Navigation Links
endpoint Adopts New Technology To Boast Most Robust IVR Validation Objective Evidence and Decrease IVR Build Timelines
Date:6/22/2012

San Francisco, CA (PRWEB) June 22, 2012

Today, endpoint (http://www.endpointclinical.com) is proud to announce that they have adopted RealityCorp’s ClinTest Voice. ClinTest Voice offers clients a dynamic, easy to use, solution for IVR test automation in a fast-paced, ever-changing industry. endpoint’s PULSE, in combination with RealityCorp’s ClinTest Voice, provides endpoint’s clients with industry leading technology, reliability, and development timelines.

“After utilizing ClinTest Voice in our environment for the last six months, it became apparent that this product would change the face of how IVR validation is performed. Testers are still responsible for creating test scripts, just like the manual process; however, that is where the similarities stop and the time savings begin. With ClinTest Voice we are able to rapidly create test scripts, including modules as dynamic as Randomization, and automate many aspects of our IVR testing in an environment where time is money. The adoption of ClinTest allows us to further leverage the rapid development of the endpoint PULSE product while providing endpoint’s Clients with the most robust objective evidence in the industry. ClinTest Voice produces objective evidence output document with embedded real-time recordings of individual prompts at the test step level, allowing users or auditors to quickly navigate to the desired test step and hear what was said by PULSE” said Jonathan Ball, Director of Testing at endpoint.

The automation of eClinical software is the next technology phase for the clinical industry. After thorough due diligence, endpoint has adopted RealityCorp’s automation solution to accurately and, more importantly, safely validate their IVR systems. With the demanding deadlines and multitude of changes from study to study, preparation of automation scripts has always been a challenge for IVR systems; however, RealityCorp’s ClinTest Voice offers endpoint a rapidly configurable way to create test scripts in an exceptionally user friendly product. The expectation that endpoint set for success criteria during their trial phase was simple; be able to save several days in testing to provide our Clients even faster turn around times and create a more consistent, bug free product to our End Users. endpoint was able to achieve this with the added benefit of the ClinTest Voice’s objective evidence documentation.

RealityCorp’s ClinTest Voice has made automated testing possible within the Clinical Trial space by:

  •     Allowing test engineers to create easy to use, configurable test scripts for even the most dynamic randomization or drug dispensation scenarios.
  •     Offering the testing team the option to never have to dial into the IVR again.
  •     Producing accurate, relevant testing objective evidence that is comprehendible at any level.
  •     Provide the most robust objective evidence by fully integrating with the associated IVR Database, providing maximum visibility for all validation activities – including data setup

About endpoint
endpoint is an innovative company dedicated to the development of the leading Integrated Voice Response (IVR/IWR) technology platforms for the life sciences industry. endpoint’s founding team has been developing IRT systems for clinical trials since 1998 and have deployed systems to small, medium and large pharma for domestic and global studies with experience across a broad range of therapeutic areas and global implementations.

Read the full story at http://www.prweb.com/releases/2012/6/prweb9630085.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
2. Chimerix Antiviral Compound, CMX001, Meets CMV Phase 2 Primary Endpoint in Allogeneic Hematopoietic Stem Cell Transplant Recipients
3. Bayer HealthCares Cotavance® Drug Eluting Balloon With Paccocath® Technology Reduced Five-Year Target Lesion Revascularization Rates by 59 Percent in PAD Patients Compared to Those Treated With Uncoated Balloon
4. Positive Clinical Study Results for BSPs HyperQ Technology
5. Arizona State University engineers aim to improve performance of technology in extreme environments
6. iBioLaunch™ Technology Successfully Applied to Modified C1 Inhibitor
7. Pitt discoveries in quantum physics could change face of technology
8. Verenium to Present at Baird Clean Technology Conference
9. Puma Biotechnology Announces Completion of Private Placement
10. Roche NimbleGen and BGI Develop Advanced MHC Region Capture Technology for Human Disease and Biomedical Research
11. Animal Biotechnology - Technologies, Markets and Companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/20/2017)... ... ... SSCI and Whitehouse Laboratories, divisions of Albany Molecular Research, Inc, are looking ... Drug Association (PDA), the New York Interphex Show will open on March 21 and ... 625 exhibitors, the educational and networking opportunities are extremely valuable. INTERPHEX is viewed as ...
(Date:3/20/2017)... ... March 20, 2017 , ... HOLLOWAY AMERICA, a leading ... it will debut a brand new pressure vessel, the intelliVessel™, at INTERPHEX 2017 ... a touch screen panel and features other revolutionary operations that promote safer, more ...
(Date:3/20/2017)... ... March 20, 2017 , ... Existing methods using LC-MS/MS suffer ... to reduce the impact on instrumentation. ICP-MS is a robust and specific analytical ... , This presentation will discuss the pros and cons of using LC-ICP-MS for ...
(Date:3/20/2017)... ... ... The fourth annual Hackaday Prize , which aims to expand the ... lives, launches today. Sponsored by Digi-Key and Microchip , the competition ... prizes to engineers, inventors and tinkerers who “build something that matters.” , The first ...
Breaking Biology Technology:
(Date:3/2/2017)... 2017 Australian stem cell and regenerative medicine ... signed an agreement with the Monash Lung Biology Network, ... Institute and Department of Pharmacology at Monash University, ... study to support the use of Cymerus™ mesenchymal stem ... Asthma is a chronic, long term lung condition ...
(Date:2/28/2017)... 27. Februar 2017  EyeLock LLC, ein marktführendes Unternehmen ... erstklassige biometrische Lösung zur Iris-Erkennung auf der ... LTE auf dem Mobile World Congress 2017 ... in Halle 3, Stand 3E10, vorstellen. ... Qualcomm Haven™ – eine Kombination aus Hardware, ...
(Date:2/22/2017)... -- With the biometrics market to exceed $10 ... that innovative and agile startups must incorporate into ... changing competitive landscape: multifactor authentication (MFA), point-of-sale (PoS), ... "Companies can no longer afford to cut corners ... Pavlakis , Industry Analyst at ABI Research. "Pairing ...
Breaking Biology News(10 mins):